A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00918203
Completed
The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2018
Locations: ImClone Investigational Site, Port Saint Lucie, Florida
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
NCT02289456
Completed
4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2018
Locations: University Cancer Institute, Boynton Beach, Florida
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
NCT02038647
Completed
This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first) when compared with placebo + paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2018
Locations: Not set, Boca Raton, Florida +3 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00404235
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving carboplatin together with ABI-007 works in treating patients with stage IV melanoma that cannot be removed by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2018
Locations: Mayo Clinic - Jacksonville, Jacksonville, Florida
Conditions: Melanoma (Skin)
Register for Updates
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
NCT02399137
Completed
The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2018
Locations: Baptist Health Med Gr Onc, LLC, Miami, Florida +2 locations
Conditions: Pancreatic Cancer
Register for Updates
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT01621243
Terminated
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402). It is made from heparin, which is a well known blood thinner. Blood thinners have been shown in prior animal and human studies to have anti-cancer effects. Necuparanib has been re-engineered from heparin to have much lower blood thinning activity while keeping the anti-tumor activity. The investigators are testing whether nec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2018
Locations: Florida Hospital Tampa, Tampa, Florida
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
NCT00112489
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin works in treating patients with persistent or recurrent stage III or stage IV uterine cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/27/2018
Locations: St. Vincent's Medical Center, Jacksonville, Florida
Conditions: Sarcoma
Register for Updates
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
NCT00467051
Completed
This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/27/2018
Locations: Lee Memorial Health System, Fort Myers, Florida +9 locations
Conditions: Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor, Testicular Yolk Sac Tumor
Register for Updates
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
NCT02151149
Completed
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
Gender:
ALL
Ages:
70 years and above
Trial Updated:
08/20/2018
Locations: Lynn Cancer Institute, Boca Raton, Florida +3 locations
Conditions: Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Large Cell, Lung Neoplasm
Register for Updates
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
NCT00915018
Completed
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will also compare the safety of the two regim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2018
Locations: Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida +5 locations
Conditions: Breast Cancer
Register for Updates
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
NCT01501487
Completed
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (LABC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2018
Locations: Morton Plant Mease Health Care, Clearwater, Florida +3 locations
Conditions: Breast Cancer
Register for Updates
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
NCT00527735
Completed
The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: M D Anderson Cancer Center- Orlando, Orlando, Florida
Conditions: Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Register for Updates